Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 23rd 2023

Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial.

In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data from the prespecified overall survival analysis of the DESTINY-Breast03 trial. The primary objective of the trial was to compare the anti-tumor activity as well as the safety and efficacy of T-DXd versus trastuzumab emtansine (T-DM1) in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

The abstract entitled ‘Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.

Questions:

  1. What is trastuzumab deruxtecan and what are its potential advantages over trastuzumab emtansine in patients with HER2+ unresectable/metastatic breast cancer? (0:15)
  2. Could you give us a brief overview of the DESTINY-Breast03 study and its interim efficacy and safety data? (2:08)
  3. What have been the findings of the overall survival analysis and the updated efficacy and safety analysis? (3:49)
  4. How clinically meaningful are these findings? (5:29)
  5. What will be the next steps in the clinical development of trastuzumab deruxtecan? (6:20)

Disclosures: Sara Hurvitz discloses grant/research support from Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen and Zymeworks.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.

Filmed as a highlight of SABCS 2022

Access more content on Breast Cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup